Spots Global Cancer Trial Database for her2 expression

Every month we try and update this database with for her2 expression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China	NCT06238284	Cervical Cancer Endometrial Can... Ovarian Cancer HER2 Expression	no intervention	18 Years - 75 Years	Chongqing University Cancer Hospital
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3	NCT04277338	Primary Breast ...	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.	NCT05203497	Breast Cancer F...	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression	NCT05957757	Non-Muscle Inva... HER2	RC48 Tislelizumab	18 Years -	RenJi Hospital
99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy	NCT05412459	HER2-positive B... Female	99mTc-DARPinG3	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3	NCT05376644	Breast Cancer F...	99mTc-ADAPT6 99mTc-DARPinG3	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
IKS014 in Advanced Solid Tumors That Express HER2	NCT05872295	Breast Cancer Gastric Cancer Gastroesophagea...	IKS014	18 Years -	Iksuda Therapeutics Ltd.
99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes	NCT05412446	Breast Cancer Female	ADAPT6-SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC	NCT05979740	Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C...	Disitamab Vedot...	18 Years -	RenJi Hospital
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC	NCT05979740	Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C...	Disitamab Vedot...	18 Years -	RenJi Hospital
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC	NCT05979740	Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C...	Disitamab Vedot...	18 Years -	RenJi Hospital
IKS014 in Advanced Solid Tumors That Express HER2	NCT05872295	Breast Cancer Gastric Cancer Gastroesophagea...	IKS014	18 Years -	Iksuda Therapeutics Ltd.
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC	NCT04686305	Locally Advance...	T-DXd Durvalumab Cisplatin Carboplatin Pemetrexed MEDI5752	18 Years -	AstraZeneca
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression	NCT05957757	Non-Muscle Inva... HER2	RC48 Tislelizumab	18 Years -	RenJi Hospital
99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes	NCT05412446	Breast Cancer Female	ADAPT6-SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3	NCT04277338	Primary Breast ...	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression	NCT05940896	Solid Tumor	Disitamab vedot...	18 Years -	RemeGen Co., Ltd.
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3	NCT04277338	Primary Breast ...	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3	NCT05376644	Breast Cancer F...	99mTc-ADAPT6 99mTc-DARPinG3	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes	NCT05412446	Breast Cancer Female	ADAPT6-SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes	NCT05412446	Breast Cancer Female	ADAPT6-SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
99mTc-ADAPT6-based HER2 Imaging in Breast Cancer	NCT03991260	Breast Cancer	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression	NCT05940896	Solid Tumor	Disitamab vedot...	18 Years -	RemeGen Co., Ltd.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: